The efficacy and tolerability of immunobiologic therapy in patients with rheumatoid arthritis

Iaremenko O.B. ¹, Ivashkovskyi O.I. ², Fedkov D.L. ³

• ¹ДУ «Національний науковий центр «Інститут кардіології ім. М.Д. Стражеска» НАМН України», Київ
• ²Олександрівська клінічна лікарня, Київ
• ³O.O. Bohomolets National Medical University, Kyiv

Summary. Summary. The efficiency and tolerability of the tumor necrosis factor-α (TNF-α) inhibitors and rituximab (RT) were studied in 11 patients with rheumatoid arthritis (RA). After 3 months of biological therapy (BT) the RA activity considerably decreased and the functional state of the patients improved: DAS28 decreased by 27,9%, HAQ — 40%, canadian pharmacy universities duration of morning stiffness decreased in 4.8 times. The reliable changes remained stable during 9 months of the treatment. After 3 months the C-reactive protein level and the erythrocyte sedimentation rate decreased respectively by 58% and 32.9%, further observed slight increase in